Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 593 entries
Sorted by: Best Match Show Resources per page
Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt.

Journal of ginseng research

Kwon HW, Shin JH, Cho HJ, Rhee MH, Park HJ.
PMID: 26843825
J Ginseng Res. 2016 Jan;40(1):76-85. doi: 10.1016/j.jgr.2015.05.004. Epub 2015 May 21.

BACKGROUND: Binding of adhesive proteins (i.e., fibrinogen, fibronectin, vitronectin) to platelet integrin glycoprotein IIb/IIIa (αIIb/β3) by various agonists (thrombin, collagen, adenosine diphosphate) involve in strength of thrombus. This study was carried out to evaluate the antiplatelet effect of total...

Cite
Kwon HW, Shin JH, Cho HJ, et al. Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt. J Ginseng Res. 2015;40(1):76-85doi: 10.1016/j.jgr.2015.05.004.
Kwon, H. W., Shin, J. H., Cho, H. J., Rhee, M. H., & Park, H. J. (2016). Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt. Journal of ginseng research, 40(1), 76-85. https://doi.org/10.1016/j.jgr.2015.05.004
Kwon, Hyuk-Woo, et al. "Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt." Journal of ginseng research vol. 40,1 (2016): 76-85. doi: https://doi.org/10.1016/j.jgr.2015.05.004
Kwon HW, Shin JH, Cho HJ, Rhee MH, Park HJ. Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt. J Ginseng Res. 2016 Jan;40(1):76-85. doi: 10.1016/j.jgr.2015.05.004. Epub 2015 May 21. PMID: 26843825; PMCID: PMC4703804.
Copy Download .nbib Format: NLM
Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer.

Oncology and therapy

Adjiri A.
PMID: 28261638
Oncol Ther. 2016;4(1):17-33. doi: 10.1007/s40487-015-0015-6. Epub 2016 Jan 20.

Cancer cells continue to challenge scientists and oncologists due to the phenomenon of resistance. Moreover, recurrence, as seen in many treated patients, shows that currently-used anti-cancer drugs are unable to prevent the development of new cancer cells harboring new...

Cite
Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther. 2016;4(1):17-33doi: 10.1007/s40487-015-0015-6.
Adjiri, A. (2016). Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncology and therapy, 4(1), 17-33. https://doi.org/10.1007/s40487-015-0015-6
Adjiri, Adouda. "Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer." Oncology and therapy vol. 4,1 (2016): 17-33. doi: https://doi.org/10.1007/s40487-015-0015-6
Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther. 2016;4(1):17-33. doi: 10.1007/s40487-015-0015-6. Epub 2016 Jan 20. PMID: 28261638; PMCID: PMC5315067.
Copy Download .nbib Format: NLM
The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making.

Interventional cardiology clinics

Gurbel PA, Tantry US.
PMID: 28582187
Interv Cardiol Clin. 2013 Oct;2(4):607-614. doi: 10.1016/j.iccl.2013.05.009. Epub 2013 Jul 10.

Clopidogrel (a widely used second-generation thienopyridine) therapy is associated with an unpredictable pharmacodynamic response whereby approximately 1 in 3 patients will have a high on-treatment platelet reactivity to adenosine diphosphate. High on-treatment platelet reactivity is an established risk factor...

Cite
Gurbel PA, Tantry US. The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interv Cardiol Clin. 2013;2(4):607-614doi: 10.1016/j.iccl.2013.05.009.
Gurbel, P. A., & Tantry, U. S. (2013). The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interventional cardiology clinics, 2(4), 607-614. https://doi.org/10.1016/j.iccl.2013.05.009
Gurbel, Paul A, and Tantry, Udaya S. "The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making." Interventional cardiology clinics vol. 2,4 (2013): 607-614. doi: https://doi.org/10.1016/j.iccl.2013.05.009
Gurbel PA, Tantry US. The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interv Cardiol Clin. 2013 Oct;2(4):607-614. doi: 10.1016/j.iccl.2013.05.009. Epub 2013 Jul 10. PMID: 28582187.
Copy Download .nbib Format: NLM
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Oncotarget

Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.
PMID: 29545922
Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.

Targeting the DNA damage response (DDR) in tumors with defective DNA repair is a clinically successful strategy. The RAS/RAF/MEK/ERK signalling pathway is frequently deregulated in human cancers. In this study, we explored the effects of MEK inhibition on the...

Cite
Vena F, Jia R, Esfandiari A, et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018;9(14):11592-11603doi: 10.18632/oncotarget.24294.
Vena, F., Jia, R., Esfandiari, A., Garcia-Gomez, J. J., Rodriguez-Justo, M., Ma, J., Syed, S., Crowley, L., Elenbaas, B., Goodstal, S., Hartley, J. A., & Hochhauser, D. (2018). MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget, 9(14), 11592-11603. https://doi.org/10.18632/oncotarget.24294
Vena, Francesca, et al. "MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models." Oncotarget vol. 9,14 (2018): 11592-11603. doi: https://doi.org/10.18632/oncotarget.24294
Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20. PMID: 29545922; PMCID: PMC5837749.
Copy Download .nbib Format: NLM
Use of suppression subtractive hybridization to identify genetic differences between differentially virulent genotypes of Paenibacillus larvae, the etiological agent of American Foulbrood of honeybees.

Environmental microbiology reports

Fünfhaus A, Ashiralieva A, Borriss R, Genersch E.
PMID: 23765853
Environ Microbiol Rep. 2009 Aug;1(4):240-50. doi: 10.1111/j.1758-2229.2009.00039.x. Epub 2009 Jun 12.

Paenibacillus larvae is the causative agent of American Foulbrood of honeybees, a fatal brood disease not only killing infected larvae but also lethal to infected colonies. Recently four different genotypes of P. larvae (enterobacterial repetitive intergenic consensus I-IV) have...

Cite
Fünfhaus A, Ashiralieva A, Borriss R, et al. Use of suppression subtractive hybridization to identify genetic differences between differentially virulent genotypes of Paenibacillus larvae, the etiological agent of American Foulbrood of honeybees. Environ Microbiol Rep. 2009;1(4):240-50doi: 10.1111/j.1758-2229.2009.00039.x.
Fünfhaus, A., Ashiralieva, A., Borriss, R., & Genersch, E. (2009). Use of suppression subtractive hybridization to identify genetic differences between differentially virulent genotypes of Paenibacillus larvae, the etiological agent of American Foulbrood of honeybees. Environmental microbiology reports, 1(4), 240-50. https://doi.org/10.1111/j.1758-2229.2009.00039.x
Fünfhaus, Anne, et al. "Use of suppression subtractive hybridization to identify genetic differences between differentially virulent genotypes of Paenibacillus larvae, the etiological agent of American Foulbrood of honeybees." Environmental microbiology reports vol. 1,4 (2009): 240-50. doi: https://doi.org/10.1111/j.1758-2229.2009.00039.x
Fünfhaus A, Ashiralieva A, Borriss R, Genersch E. Use of suppression subtractive hybridization to identify genetic differences between differentially virulent genotypes of Paenibacillus larvae, the etiological agent of American Foulbrood of honeybees. Environ Microbiol Rep. 2009 Aug;1(4):240-50. doi: 10.1111/j.1758-2229.2009.00039.x. Epub 2009 Jun 12. PMID: 23765853.
Copy Download .nbib Format: NLM
Responses of freshwater prawn,Macrobrachium rosenbergii, to chemical attractants.

Journal of chemical ecology

Harpaz S, Kahan D, Galun R, Moore I.
PMID: 24302460
J Chem Ecol. 1987 Sep;13(9):1957-65. doi: 10.1007/BF01014678.

Chemoreception in the adults of the freshwater prawnMacrobrachium rosenbergii was investigated under controlled laboratory conditions, using behavioral assays. Tests were carried out on groups, as well as on individuals, all at their intermolt stages of the molt cycle, and...

Cite
Harpaz S, Kahan D, Galun R, et al. Responses of freshwater prawn,Macrobrachium rosenbergii, to chemical attractants. J Chem Ecol. 1987;13(9):1957-65doi: 10.1007/BF01014678.
Harpaz, S., Kahan, D., Galun, R., & Moore, I. (1987). Responses of freshwater prawn,Macrobrachium rosenbergii, to chemical attractants. Journal of chemical ecology, 13(9), 1957-65. https://doi.org/10.1007/BF01014678
Harpaz, S, et al. "Responses of freshwater prawn,Macrobrachium rosenbergii, to chemical attractants." Journal of chemical ecology vol. 13,9 (1987): 1957-65. doi: https://doi.org/10.1007/BF01014678
Harpaz S, Kahan D, Galun R, Moore I. Responses of freshwater prawn,Macrobrachium rosenbergii, to chemical attractants. J Chem Ecol. 1987 Sep;13(9):1957-65. doi: 10.1007/BF01014678. PMID: 24302460.
Copy Download .nbib Format: NLM
Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct.

Physiological reports

Bune LT, Larsen JR, Thaning P, Bune NE, Rasmussen P, Rosenmeier JB.
PMID: 24303097
Physiol Rep. 2013 Jun;1(1):e00003. doi: 10.1002/PHY2.3. Epub 2013 May 21.

Acute myocardial infarction continues to be a major cause of morbidity and mortality. Timely reperfusion can substantially improve outcomes and the administration of cardioprotective substances during reperfusion is therefore highly attractive. Adenosine diphosphate (ADP) and uridine-5-triphoshate (UTP) are both...

Cite
Bune LT, Larsen JR, Thaning P, et al. Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct. Physiol Rep. 2013;1(1):e00003doi: 10.1002/PHY2.3.
Bune, L. T., Larsen, J. R., Thaning, P., Bune, N. E., Rasmussen, P., & Rosenmeier, J. B. (2013). Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct. Physiological reports, 1(1), e00003. https://doi.org/10.1002/PHY2.3
Bune, Laurids T, et al. "Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct." Physiological reports vol. 1,1 (2013): e00003. doi: https://doi.org/10.1002/PHY2.3
Bune LT, Larsen JR, Thaning P, Bune NE, Rasmussen P, Rosenmeier JB. Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct. Physiol Rep. 2013 Jun;1(1):e00003. doi: 10.1002/PHY2.3. Epub 2013 May 21. PMID: 24303097; PMCID: PMC3831933.
Copy Download .nbib Format: NLM
Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures.

Current therapeutic research, clinical and experimental

Rao TR, Usha PR, Naidu MU, Gogtay JA, Meena M.
PMID: 24944416
Curr Ther Res Clin Exp. 2003 Nov;64(9):685-96. doi: 10.1016/j.curtheres.2003.09.014.

BACKGROUND: The role of platelets in acute cardiovascular atherothrombotic events has been well established and attention has focused on platelet inhibition therapy. Clopidogrel is a novel thienopyridine inhibitor of adenosine diphosphate-induced platelet activation. Recent studies have shown that in...

Cite
Rao TR, Usha PR, Naidu MU, et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 2003;64(9):685-96doi: 10.1016/j.curtheres.2003.09.014.
Rao, T. R., Usha, P. R., Naidu, M. U., Gogtay, J. A., & Meena, M. (2003). Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Current therapeutic research, clinical and experimental, 64(9), 685-96. https://doi.org/10.1016/j.curtheres.2003.09.014
Rao, Takallapalli Ramesh Kumar, et al. "Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures." Current therapeutic research, clinical and experimental vol. 64,9 (2003): 685-96. doi: https://doi.org/10.1016/j.curtheres.2003.09.014
Rao TR, Usha PR, Naidu MU, Gogtay JA, Meena M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 2003 Nov;64(9):685-96. doi: 10.1016/j.curtheres.2003.09.014. PMID: 24944416; PMCID: PMC4053054.
Copy Download .nbib Format: NLM
An update on PARP inhibitors for the treatment of cancer.

OncoTargets and therapy

Benafif S, Hall M.
PMID: 25750544
Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.

The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers. This article attempts to summarize the rationale and theory...

Cite
Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015;8:519-28doi: 10.2147/OTT.S30793.
Benafif, S., & Hall, M. (2015). An update on PARP inhibitors for the treatment of cancer. OncoTargets and therapy, 8519-28. https://doi.org/10.2147/OTT.S30793
Benafif, Sarah, and Hall, Marcia. "An update on PARP inhibitors for the treatment of cancer." OncoTargets and therapy vol. 8 (2015): 519-28. doi: https://doi.org/10.2147/OTT.S30793
Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015. PMID: 25750544; PMCID: PMC4348139.
Copy Download .nbib Format: NLM
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.

Clinical pharmacology : advances and applications

Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA.
PMID: 24353446
Clin Pharmacol. 2013 Dec 09;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013.

Recent candidate gene studies using a human liver bank and in vivo validation in healthy volunteers identified polymorphisms in cytochrome P450 (CYP) 3A4 gene (CYP3A4*22), Ah-receptor nuclear translocator (ARNT), and peroxisome proliferator-activated receptor-α (PPAR-α) genes that are associated with...

Cite
Kreutz RP, Owens J, Jin Y, et al. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol. 2013;5:185-92doi: 10.2147/CPAA.S53151.
Kreutz, R. P., Owens, J., Jin, Y., Nystrom, P., Desta, Z., Kreutz, Y., Breall, J. A., Li, L., Chiang, C., Kovacs, R. J., & Flockhart, D. A. (2013). Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clinical pharmacology : advances and applications, 5185-92. https://doi.org/10.2147/CPAA.S53151
Kreutz, Rolf P, et al. "Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response." Clinical pharmacology : advances and applications vol. 5 (2013): 185-92. doi: https://doi.org/10.2147/CPAA.S53151
Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol. 2013 Dec 09;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013. PMID: 24353446; PMCID: PMC3862586.
Copy Download .nbib Format: NLM
Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates.

Blood transfusion = Trasfusione del sangue

Koessler J, Weber K, Koessler A, Yilmaz P, Boeck M, Kobsar A.
PMID: 26674810
Blood Transfus. 2016 Nov;14(6):545-551. doi: 10.2450/2015.0073-15. Epub 2015 Nov 17.

BACKGROUND: The storage of platelets affects platelet integrity and functionality, a process named platelet storage lesion (PSL). Reduced adenosine diphosphate (ADP)-induced platelet aggregation is a typical manifestation of PSL. However, the role of ADP receptors in this context has...

Cite
Koessler J, Weber K, Koessler A, et al. Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates. Blood Transfus. 2015;14(6):545-551doi: 10.2450/2015.0073-15.
Koessler, J., Weber, K., Koessler, A., Yilmaz, P., Boeck, M., & Kobsar, A. (2016). Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates. Blood transfusion = Trasfusione del sangue, 14(6), 545-551. https://doi.org/10.2450/2015.0073-15
Koessler, Juergen, et al. "Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates." Blood transfusion = Trasfusione del sangue vol. 14,6 (2016): 545-551. doi: https://doi.org/10.2450/2015.0073-15
Koessler J, Weber K, Koessler A, Yilmaz P, Boeck M, Kobsar A. Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates. Blood Transfus. 2016 Nov;14(6):545-551. doi: 10.2450/2015.0073-15. Epub 2015 Nov 17. PMID: 26674810; PMCID: PMC5111382.
Copy Download .nbib Format: NLM
Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation.

Pharmacognosy magazine

Chaudhuri D, Ghate NB, Singh SS, Mandal N.
PMID: 25829764
Pharmacogn Mag. 2015 Apr-Jun;11(42):269-76. doi: 10.4103/0973-1296.153078.

BACKGROUND: Spondias pinnata has been reported for its efficient anticancer effects, but the studies were mostly focused on its extract.OBJECTIVE: Since its bioactive compounds are largely unknown, this study was designed to characterize the lead components present in it...

Cite
Chaudhuri D, Ghate NB, Singh SS, et al. Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacogn Mag. 2015;11(42):269-76doi: 10.4103/0973-1296.153078.
Chaudhuri, D., Ghate, N. B., Singh, S. S., & Mandal, N. (2015). Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacognosy magazine, 11(42), 269-76. https://doi.org/10.4103/0973-1296.153078
Chaudhuri, Dipankar, et al. "Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation." Pharmacognosy magazine vol. 11,42 (2015): 269-76. doi: https://doi.org/10.4103/0973-1296.153078
Chaudhuri D, Ghate NB, Singh SS, Mandal N. Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacogn Mag. 2015 Apr-Jun;11(42):269-76. doi: 10.4103/0973-1296.153078. PMID: 25829764; PMCID: PMC4378123.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 593 entries